drinking with glp-1 Ep. 50: More Studies Point to GLP-1s to Treat Addiction GLP-1 drugs may delay alcohol's

Resume at the last tolerated dose

Can breakthroughs in dermal and transdermal macromolecule delivery surmount existing barriers and revolutionize future therapeutics

In the STEP 1 trial, patients on semaglutide 2.4 mg lost an average of 14.9% of their body weight by week 68

After 28 days, users reported 40% less irritation, 94% smoother skin, up to 33% fewer deep forehead lines, and 83% felt their skin fully recovered

Interestingly, differences in prooxidative parameters were more profound in acute coronary syndrome patients compared with coronary artery disease patients indicating that the acute form of coronary artery disease is more susceptible to oxidative damage, suggesting that use of antioxidant therapy may be warranted to reduce oxidative stress in this disorder (154)

The most effective approach typically combines nutrition changes, regular physical activity (especially a mix of resistance training and cardio), adequate sleep, and stress management